May 2003
Volume 44, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2003
Immunohistochemical Profile and Histochemical Analysis of Primary Acquired Melanosis of the Conjunctiva
Author Affiliations & Notes
  • M.W. Dorey
    Ophthalmology and Pathology, University of Ottawa, Ottawa, ON, Canada
  • S. Brownstein
    Ophthalmology and Pathology, University of Ottawa, Ottawa, ON, Canada
  • H. Faraji
    Ophthalmology and Pathology, University of Ottawa, Ottawa, ON, Canada
  • S. Robertson
    Pathology, University of Ottawa, Ottawa, ON, Canada
  • R. Prokopetz
    Dermatology and Pathology, University of Ottawa, Ottawa, ON, Canada
  • D.R. Jordan
    Ophthalmology, University of Ottawa, Ottawa, ON, Canada
  • Footnotes
    Commercial Relationships  M.W. Dorey, None; S. Brownstein, None; H. Faraji, None; S. Robertson, None; R. Prokopetz, None; D.R. Jordan, None.
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 2427. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M.W. Dorey, S. Brownstein, H. Faraji, S. Robertson, R. Prokopetz, D.R. Jordan; Immunohistochemical Profile and Histochemical Analysis of Primary Acquired Melanosis of the Conjunctiva . Invest. Ophthalmol. Vis. Sci. 2003;44(13):2427.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To develop ancillary diagnostic tests to identify and confirm the presence and extent of atypia amongst the melanocytic lesions of primary acquired melanosis (PAM) of the conjunctiva. Methods: 10 specimens of PAM with atypia were obtained through the ocular pathology registry at the University of Ottawa Eye Institute from May 1994 to November 2002. Sections from each formalin-fixed paraffin-embedded specimen were stained with hematoxylin-eosin (including on bleached specimens) and periodic acid-Schiff (PAS) and immunostained with anti-S-100, HMB-45 (anti-gp100), melanoma cocktail (anti-melan-A and HMB-45), pan melanoma cocktail (anti-melan-A, HMB-45, and anti-tyrosinase), anti-melan-A, anti-Ki67 (MIB-1), anti-tyrosinase (T311), anti-microphthalmia-associated transcription factor (D5), and vimentin. These specimens were processed with the 3,3 diaminobenzidine (DAB) substrate and the Vector Red substrate methods. We similarly looked at PAM lesions without atypia, conjunctiva, as well as choroidal melanomas as controls. Results: The melanocytes were best demonstrated with the melanoma cocktail (anti-melan-A and HMB-45), pan melanoma cocktail (anti-melan-A, HMB-45, and anti-tyrosinase), anti-melan-A, and anti-tyrosinase (T311), all of which showed 100% positive staining. The melanocytes were often weakly stained by anti-MIB-1, anti-microphthalmia-associated transcription factor, and anti-S-100 and were negative in the atypical melanocytes in some of the cases. HMB-45 showed the highest specificity to atypical melanocytes (80%) but was less sensitive than the newer markers (80%). In the majority of cases, the DAB method could not differentiate between brown melanin pigment and brown pigmented immunostain in the atypical melanocytes, making it difficult to establish the presence and extent of atypia with these immunostains. The vector red method allowed easy differentiation amongst the melanin pigment from the red pigmented immunostain in the atypical melanocytes. Conclusions: The popular DAB method is often not useful in the identification of melanocytes in PAM and should be replaced by the vector red method. We believe our study is the first to demonstrate that HMB-45 is the only antibody with relatively high specificity to the atypical melanocytes of PAM. The results from this study may aid in making a more timely, definitive, and complete histopathological diagnosis of PAM with atypia.

Keywords: conjunctiva • melanocytes • pathology: human 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×